Author Affiliations: Deutsches Herzzentrum, Technische Universität, Munich, Germany.
Cardiogenic shock complicating acute myocardial infarction (AMI) is one of the most serious and challenging conditions in cardiovascular medicine, with up to two thirds of patients dying within a few weeks.1,2 According to data from a national registry of nearly 300 000 patients with ST-segment elevation AMI, the overall incidence of cardiogenic shock (diagnosed at both presentation and after admission) was 8.6%.3
Ndrepepa G, Schömig A, Kastrati A. Lack of Benefit From Nitric Oxide Synthase Inhibition in Patients With Cardiogenic Shock: Looking for the Reasons. JAMA. 2007;297(15):1711–1713. doi:10.1001/jama.297.15.1711
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: